The evidence suggests women may be more vulnerable to weight-loss-related shedding
Among those who did not adhere to their initial treatment within the 1year followup period, 90.5% of metformin initiators and 94.2% of GLP1RA initiators did not start another glucoselowering therapy afterward
Emily Brown, John P H Wilding, Thomas M Barber, Uazman Alam, Daniel J Cuthbertson
Eli Lilly is testing retatrutide that affects GLP-1, GIP and glucagon receptors
Migraine and Insulin Resistance: Clinical Evidence and Observations Although the exact pathophysiology of migraine remains incompletely understood, growing evidence highlights a significant metabolic component, particularly related to insulin resistance (IR) and overall metabolic dysfunction
Its weight loss data (20.1% at 60 weeks) also exceeds survodutide's Phase 2 results (18.7% at 46 weeks)